Skip to content

The Delphi Trial - I(RCT)².

The Delphi Trial - I(RCT)². International Randomized Clinical Trial of Rheumatoid Craniocervical Treatment. An Intervention-Prognostic Trial comparing ‘early’ surgery with natural history.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21485
Enrollment
250
Registered
2005-10-31
Start date
2005-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis, atlantoaxial subluxation without neurological deficits. AADI 5-12 mm

Interventions

Surgical treatment: Different surgical opportunities and techniques for cervical fixation exist. The choice of technique depends on the severity of the cervical spine involvement and the surgeon’s pre

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Rheumatoid Arthritis patients, seropositive; 2. Age 18-70; 3. Ranawat I and II: no neurological impairment; 4. C1-C2 subluxation: AADI: 5-12 mm; 5. C1-C2 subluxation reducible or irreducible; 6. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Ranawat IIIA and IIIB: neurological impairment; 2. Severe comorbidity; 3. Previous craniocervical operations; 4. C1-C2 subluxation: AADI 12 mm or PADI < 10 mm; 5. MRI incompatibility.

Design outcomes

Primary

MeasureTime frame
The primary outcome is the occurrence of a major event: 1. Neurological disability (paraesthesias, worsened Myelopathy Disability Index > 3 points); 2. Radiological progression (signs of myelopathy on MRI, impression of brainstem by vertical translocation, AADI > 12 mm, Vertical translocation); 3. Surgery (B) or resurgery (A) in case of progression to a stadium that longer wait and see will result in inevitable neurological deficit or death; 4. Death (all causes).

Secondary

MeasureTime frame
Secondary outcome measures are Ranawat, ASIA, DAS-28, VAS, EuroQol, SF-36, functional X-ray and MRI. The outcome will be evaluated at fixed intervals and a Kaplan Meier Survival Analysis will be performed.

Contacts

Public ContactJ.F.C. Wolfs

Leiden University Medical Center (LUMC) P.O. Box 9600

j.f.c.wolfs@lumc.nl+31 (0)71 5269111 / +31 (0)6 27993945

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)